- Home
- AMZE vs INAB Comparison
AMZE vs INAB Comparison
Compare AMZE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | INAB |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMZE | INAB |
|---|---|---|
| Price | $0.13 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.6M | 56.7K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.12 |
| 52 Week High | $11.76 | $4.20 |
Technical Indicators
Market Signals| Indicator | AMZE | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 48.63 |
| Support Level | $0.12 | $1.35 |
| Resistance Level | $0.20 | $2.14 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 5.01 | 63.33 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.